Measure Airway Compliance by Endobronchial Optical Coherence Tomography

Optical Coherence Tomography （OCT）is a novel, non-invasive, high resolution special optical imaging techniques. In airway, Measure airway area and airway wall thickness is the most usage of Endobronchial Optical Coherence Tomography (EB-OCT）. Recently, the new protocol of EB-OCT is used to measure airway compliance, We will establish a new methodology of EB-OCT for measuring airway compliance, which will provide a new means to study respiratory diseases.

Inclusion Criteria:Regardless of gender, age 18-70 years old;Patients with clinical diagnosis of pulmonary nodules, COPD, asthma or restrictive pulmonary diseases;Can tolerate bronchoscopy patients;Sign the informed consent form.Exclusion Criteria:Suffering from any of the following respiratory diseases: bronchiectasis, etc;Have malignant tumors that are not completely remission or cured;The patient's systemic infection is not controlled;Recent use of immunosuppressants, recent use of anticoagulants (such as warfarin or aspirin within 2 weeks of drugs that affect blood clotting function);Serious other systemic diseases: myocardial infarction, unstable angina, cirrhosis, acute glomerulonephritis, etc.;Those who are positive for syphilis, HIV, HBV, and HCV antibodies;Patients with coagulation dysfunction diseases, such as hemophilia, giant platelet syndrome, platelet weakness, etc.;Severe renal impairment, serum creatinine > 1.5 times the upper limit of normal value;Liver disease or liver function impairment: ALT, AST, total bilirubin > 2 times the upper limit of normal value;Those with a history of mental illness or suicide, a history of epilepsy or other central nervous system diseases;12-lead ECG showing severe arrhythmias (such as ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or conduction abnormalities of the heart of grade II and above;Those who are allergic to catheters and related materials required for experiments;Subjects who have received any other clinical studies within 3 months prior to enrollment;Those who have poor compliance and difficulty in completing the study;Any condition that the clinician believes may increase the risk to the patient or interfere with the clinical study.